Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology platformEVX-04 is a therapeutic cancer vaccine candidate ...
Mile PLC , the AIM, FSE, and OTC.BLLYF listed exploration and development company with projects in Greenland, Finland and Italy, is pleased to announce that it has entered into a Binding Head of Terms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback